Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Cy Molecular Diagnostics Inc. currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This 1 active matter is handled by 1 distinct examiner, EMMA RUTH HOPPE, who is also identified as the busiest examiner for the portfolio. Because there is only 1 distinct art unit involved, the prosecution strategy is concentrated in a specific regulatory environment.
The data shows that EMMA RUTH HOPPE is responsible for 1 busiest examiner pending action, which accounts for the total volume of pending office actions. This alignment between the total count of 1 pending office action and the 1 distinct examiner indicates a point of contact for the company's current patent applications. Practitioners should note that the involvement of only 1 distinct art unit simplifies the technical landscape for this portfolio. The focus on Biotechnology & Pharmaceuticals requires specialized expertise, yet the scope of the 1 distinct examiner's review suggests a manageable prosecution pipeline. The 1 busiest examiner pending action represents the entirety of the current workload, allowing for a focused response strategy.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HOPPE, EMMA RUTH | 1 | 42.1% | +56.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18035850 | Compositions and Methods for High Sensitivity Detection of Rare Mutations | HOPPE, EMMA RUTH | 49d overdue |
| Art Unit | Apps |
|---|---|
| 1683 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18035850 | Compositions and Methods for High Sensitivity Detection of Rare Mutations | HOPPE, EMMA RUTH | 1683 | §103 | Final Rejection | 49d overdue | Pending | May 08, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial